BACKGROUND: Long-term clinical outcomes in children with very-early onset (VEO; diagnosis in utero or within the first 18 months of life) autosomal dominant polycystic kidney disease (ADPKD) are currently not well understood. We conducted a longitudinal retrospective cohort study to assess the association between VEO status and adverse clinical outcomes. METHODS: Seventy patients with VEO-ADPKD matched (by year of birth, sex and race/ethnicity) to 70 patients with non-VEO-ADPKD who participated in research at the University of Colorado were studied. Kaplan-Meier survival analysis was performed. The predictor was VEO status, and outcomes were progression to end-stage renal disease (ESRD), development of hypertension, progression to estimated glomerular filtration rate (eGFR <90 ml/min/1.73 m2), glomerular hyperfiltration (eGFR ≥140 ml/min/1.73 m2) and height-adjusted total kidney volume (htTKV) measured by MRI ≥600 ml/m. RESULTS: Median follow-up was until 16.0 years of age. There were only 4 ESRD events during the follow-up period, all in the VEO group (p < 0.05). VEO patients were more likely to develop hypertension (hazard ratio, HR 3.15, 95% CI 1.86-5.34; p < 0.0001) and to progress to eGFR <90 ml/min/1.73 m2 (HR 1.97, 95% CI 1.01-3.84; p < 0.05) than non-VEO patients. There was no difference between groups in the development of glomerular hyperfiltration (HR 0.89, 95% CI 0.56-1.42; p = 0.62). There were only 7 patients who progressed to htTKV ≥600 ml/m, 4 in the VEO group and 3 in the non-VEO group (p < 0.01). CONCLUSIONS: Several clinical outcomes are worse in patients with VEO-ADPKD compared to non-VEO ADPKD. Children with VEO-ADPKD represent a particularly high-risk group of ADPKD patients.
BACKGROUND: Long-term clinical outcomes in children with very-early onset (VEO; diagnosis in utero or within the first 18 months of life) autosomal dominant polycystic kidney disease (ADPKD) are currently not well understood. We conducted a longitudinal retrospective cohort study to assess the association between VEO status and adverse clinical outcomes. METHODS: Seventy patients with VEO-ADPKD matched (by year of birth, sex and race/ethnicity) to 70 patients with non-VEO-ADPKD who participated in research at the University of Colorado were studied. Kaplan-Meier survival analysis was performed. The predictor was VEO status, and outcomes were progression to end-stage renal disease (ESRD), development of hypertension, progression to estimated glomerular filtration rate (eGFR <90 ml/min/1.73 m2), glomerular hyperfiltration (eGFR ≥140 ml/min/1.73 m2) and height-adjusted total kidney volume (htTKV) measured by MRI ≥600 ml/m. RESULTS: Median follow-up was until 16.0 years of age. There were only 4 ESRD events during the follow-up period, all in the VEO group (p < 0.05). VEO patients were more likely to develop hypertension (hazard ratio, HR 3.15, 95% CI 1.86-5.34; p < 0.0001) and to progress to eGFR <90 ml/min/1.73 m2 (HR 1.97, 95% CI 1.01-3.84; p < 0.05) than non-VEO patients. There was no difference between groups in the development of glomerular hyperfiltration (HR 0.89, 95% CI 0.56-1.42; p = 0.62). There were only 7 patients who progressed to htTKV ≥600 ml/m, 4 in the VEO group and 3 in the non-VEO group (p < 0.01). CONCLUSIONS: Several clinical outcomes are worse in patients with VEO-ADPKD compared to non-VEO ADPKD. Children with VEO-ADPKD represent a particularly high-risk group of ADPKD patients.
Authors: Pamela R Fain; Kimberly K McFann; Matthew R G Taylor; Maryellyn Tison; Ann M Johnson; Berenice Reed; Robert W Schrier Journal: Kidney Int Date: 2005-04 Impact factor: 10.612
Authors: G M Fick; A M Johnson; J D Strain; W J Kimberling; S Kumar; M L Manco-Johnson; I T Duley; P A Gabow Journal: J Am Soc Nephrol Date: 1993-06 Impact factor: 10.121
Authors: Melissa A Cadnapaphornchai; Diana M George; Kim McFann; Wei Wang; Berenice Gitomer; John D Strain; Robert W Schrier Journal: Clin J Am Soc Nephrol Date: 2014-04-10 Impact factor: 8.237
Authors: Charlotte Gimpel; E Fred Avni; Luc Breysem; Kathrin Burgmaier; Anna Caroli; Metin Cetiner; Dieter Haffner; Erum A Hartung; Doris Franke; Jens König; Max C Liebau; Djalila Mekahli; Albert C M Ong; Lars Pape; Andrea Titieni; Roser Torra; Paul J D Winyard; Franz Schaefer Journal: Radiology Date: 2019-01-01 Impact factor: 11.105
Authors: Stéphanie De Rechter; Detlef Bockenhauer; Lisa M Guay-Woodford; Isaac Liu; Andrew J Mallett; Neveen A Soliman; Lucimary C Sylvestre; Franz Schaefer; Max C Liebau; Djalila Mekahli Journal: Kidney Int Rep Date: 2019-05-29
Authors: Charlotte Gimpel; Carsten Bergmann; Detlef Bockenhauer; Luc Breysem; Melissa A Cadnapaphornchai; Metin Cetiner; Jan Dudley; Francesco Emma; Martin Konrad; Tess Harris; Peter C Harris; Jens König; Max C Liebau; Matko Marlais; Djalila Mekahli; Alison M Metcalfe; Jun Oh; Ronald D Perrone; Manish D Sinha; Andrea Titieni; Roser Torra; Stefanie Weber; Paul J D Winyard; Franz Schaefer Journal: Nat Rev Nephrol Date: 2019-11 Impact factor: 28.314
Authors: Peter Janssens; Jean-Paul Decuypere; Stéphanie De Rechter; Luc Breysem; Dorien Van Giel; Jaak Billen; An Hindryckx; Luc De Catte; Marcella Baldewijns; Kathleen B M Claes; Karl M Wissing; Koen Devriendt; Bert Bammens; Isabelle Meyts; Vicente E Torres; Rudi Vennekens; Djalila Mekahli Journal: Kidney Int Rep Date: 2021-04-06